Hyperion Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 3:14PM CDT
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 13 Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 10:00 a.m. ET.
Hyperion Therapeutics to Present at the 26th Annual Roth Conference
GlobeNewswire - Fri Mar 07, 9:23AM CST
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 26 Annual Roth Conference on Tuesday, March 11, 2014 at 10:30 a.m. PT.
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
Business Wire - Tue Mar 04, 5:30AM CST
AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company's financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.
This Week in Biotech: 2 FDA Approvals and 3 Clinically Impressive Studies
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 2:15PM CST
With the SPDR S&P Biotech Index up 75% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Hyperion Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Feb 27, 3:13PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today reported net revenue of $18.6 million and $42.2 million for the fourth quarter and full year 2013, respectively. Hyperion's revenues are for sales of its two products for the treatment of urea cycle disorders, RAVICTI (glycerol phenylbutyrate) Oral Liquid, launched on March 1, 2013 and BUPHENYL (sodium phenylbutyrate) Tablets and Powder acquired on May 31, 2013. Adjusted net income for the fourth quarter 2013 was $4.1 million compared to an adjusted net loss of $7.9 million in the fourth quarter of 2012, an increase in net income of $12.0 million. The company ended 2013 with cash, cash equivalents and investments of $118.1 million, an increase of $9.5 million from the prior quarter.
Hyperion Therapeutics to Present at the Cowen and Company 34th Annual Healthcare Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Cowen and Company 34 Annual Healthcare Conference on Monday, March 3 at 2:50 p.m. ET.
Why Hyperion Therapeutics Inc. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 12:59PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Hyperion Therapeutics , a...
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 25, 12:28PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Hyperion Therapeutics Announces the Publication of Phase 2 Results of Glycerol Phenylbutyrate (GPB) for the Treatment of Hepatic Encephalopathy in Hepatology
GlobeNewswire - Tue Feb 25, 9:25AM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that results of the Phase 2 trial of glycerol phenylbutyrate (GPB) for the treatment of hepatic encephalopathy (HE) were published in the March 2014 issue of Hepatology. The study met its primary endpoint with significantly fewer patients treated with GPB experiencing HE events as compared to patients receiving placebo.
Zhejiang Giuseppe Garment Digs for New Customers
SinoCast - Tue Feb 25, 4:54AM CST
Zhejiang Giuseppe Garment Co., Ltd. (SZSE: 002687) revealed declining sales revenue affected by dim garment market situation in 2013. Hence, the company planned to extend customers from finance, power, and tobacco to private school and government fields.
Hyperion Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results After Market on February 27, 2014
GlobeNewswire - Mon Feb 24, 3:05PM CST
Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced that it will report fourth quarter and full year 2013 financial results after market closes on Thursday, February 27, 2014. Hyperion will host a webcast and conference call with management to discuss financial results, as well as provide a general corporate update, at 4:30 p.m. ET (1:30 p.m. PT).
Prime Resources Holdings, Inc. acquires additional shares in Mindoro Resources Ltd.
CNW Group - Fri Feb 21, 2:00AM CST
Prime Resources Holdings, Inc. ("PRHI"
Hyperion Therapeutics to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 8:15AM CST
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 13 at 2:40 p.m. ET.
Zoom Technologies inks intent to acquire Tinho
M2 - Thu Jan 16, 8:22AM CST
On January 13, 2014, Zoom Technologies, Inc. (NASDAQ: ZOOM) said it entered into a letter of intent with Tinho Union Holding Group to acquire all the outstanding shares of Tinho by issuing approximately 9.4 million new shares of the company's common stock at a valuation of USD8.6505 per share to the shareholders of Tinho.
Hyperion Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 3:09PM CST
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 32 Annual J.P. Morgan Healthcare Conference on Thursday, January 16 at 7:30 a.m. PT.
Hyperion Therapeutics (HPTX) Jumps: Stock Adds 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 19, 7:39AM CST
Hyperion Therapeutics, Inc. was a big mover last session, as its shares rose over 5% on the day.
Hyperion Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 26, 3:05PM CST
Hyperion Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to present at the 25 Annual Piper Jaffray Healthcare Conference on Wednesday, December 4 at 2:00 p.m. ET.